REPLIGEN CORP (RGEN) Fundamental Analysis & Valuation

NASDAQ:RGEN • US7599161095

119.99 USD
-5.04 (-4.03%)
At close: Mar 6, 2026
119.99 USD
0 (0%)
After Hours: 3/6/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This RGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Overall RGEN gets a fundamental rating of 5 out of 10. We evaluated RGEN against 57 industry peers in the Life Sciences Tools & Services industry. RGEN has an excellent financial health rating, but there are some minor concerns on its profitability. RGEN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. RGEN Profitability Analysis

1.1 Basic Checks

  • In the past year RGEN was profitable.
  • In the past year RGEN had a positive cash flow from operations.
  • Of the past 5 years RGEN 4 years were profitable.
  • In the past 5 years RGEN always reported a positive cash flow from operatings.
RGEN Yearly Net Income VS EBIT VS OCF VS FCFRGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

1.2 Ratios

  • RGEN has a Return On Assets of 1.66%. This is in the better half of the industry: RGEN outperforms 70.18% of its industry peers.
  • With a decent Return On Equity value of 2.32%, RGEN is doing good in the industry, outperforming 71.93% of the companies in the same industry.
  • RGEN's Return On Invested Capital of 1.65% is fine compared to the rest of the industry. RGEN outperforms 61.40% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for RGEN is significantly below the industry average of 11.61%.
  • The 3 year average ROIC (1.45%) for RGEN is below the current ROIC(1.65%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.66%
ROE 2.32%
ROIC 1.65%
ROA(3y)0.67%
ROA(5y)2.96%
ROE(3y)0.95%
ROE(5y)3.98%
ROIC(3y)1.45%
ROIC(5y)3.72%
RGEN Yearly ROA, ROE, ROICRGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 4 6 8

1.3 Margins

  • RGEN has a Profit Margin of 6.62%. This is in the better half of the industry: RGEN outperforms 73.68% of its industry peers.
  • RGEN's Profit Margin has declined in the last couple of years.
  • The Operating Margin of RGEN (8.03%) is better than 66.67% of its industry peers.
  • In the last couple of years the Operating Margin of RGEN has declined.
  • With a decent Gross Margin value of 52.65%, RGEN is doing good in the industry, outperforming 68.42% of the companies in the same industry.
  • RGEN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 8.03%
PM (TTM) 6.62%
GM 52.65%
OM growth 3Y-31%
OM growth 5Y-16.8%
PM growth 3Y-34.16%
PM growth 5Y-16.54%
GM growth 3Y-2.53%
GM growth 5Y-1.65%
RGEN Yearly Profit, Operating, Gross MarginsRGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. RGEN Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RGEN is destroying value.
  • Compared to 1 year ago, RGEN has more shares outstanding
  • Compared to 5 years ago, RGEN has more shares outstanding
  • The debt/assets ratio for RGEN has been reduced compared to a year ago.
RGEN Yearly Shares OutstandingRGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
RGEN Yearly Total Debt VS Total AssetsRGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • An Altman-Z score of 5.95 indicates that RGEN is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 5.95, RGEN belongs to the top of the industry, outperforming 91.23% of the companies in the same industry.
  • The Debt to FCF ratio of RGEN is 5.91, which is a neutral value as it means it would take RGEN, 5.91 years of fcf income to pay off all of its debts.
  • RGEN has a Debt to FCF ratio of 5.91. This is in the better half of the industry: RGEN outperforms 68.42% of its industry peers.
  • A Debt/Equity ratio of 0.26 indicates that RGEN is not too dependend on debt financing.
  • RGEN has a Debt to Equity ratio (0.26) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.91
Altman-Z 5.95
ROIC/WACC0.15
WACC10.77%
RGEN Yearly LT Debt VS Equity VS FCFRGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.3 Liquidity

  • RGEN has a Current Ratio of 8.37. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
  • RGEN has a better Current ratio (8.37) than 91.23% of its industry peers.
  • A Quick Ratio of 7.12 indicates that RGEN has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 7.12, RGEN belongs to the top of the industry, outperforming 89.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.37
Quick Ratio 7.12
RGEN Yearly Current Assets VS Current LiabilitesRGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. RGEN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 15.54% over the past year.
  • The Earnings Per Share has been growing slightly by 0.60% on average over the past years.
  • Looking at the last year, RGEN shows a decrease in Revenue. The Revenue has decreased by -6.05% in the last year.
  • RGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.05% yearly.
EPS 1Y (TTM)15.54%
EPS 3Y-19.52%
EPS 5Y0.6%
EPS Q2Q%11.36%
Revenue 1Y (TTM)-6.05%
Revenue growth 3Y-2.7%
Revenue growth 5Y15.05%
Sales Q2Q%18.12%

3.2 Future

  • Based on estimates for the next years, RGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 26.07% on average per year.
  • The Revenue is expected to grow by 15.56% on average over the next years. This is quite good.
EPS Next Y16.45%
EPS Next 2Y20.77%
EPS Next 3Y22.86%
EPS Next 5Y26.07%
Revenue Next Year12.66%
Revenue Next 2Y13.68%
Revenue Next 3Y14.28%
Revenue Next 5Y15.56%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
RGEN Yearly Revenue VS EstimatesRGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B 2.5B
RGEN Yearly EPS VS EstimatesRGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

2

4. RGEN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 70.17, which means the current valuation is very expensive for RGEN.
  • The rest of the industry has a similar Price/Earnings ratio as RGEN.
  • Compared to an average S&P500 Price/Earnings ratio of 26.29, RGEN is valued quite expensively.
  • With a Price/Forward Earnings ratio of 60.26, RGEN can be considered very expensive at the moment.
  • RGEN's Price/Forward Earnings ratio is in line with the industry average.
  • RGEN is valuated expensively when we compare the Price/Forward Earnings ratio to 24.57, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 70.17
Fwd PE 60.26
RGEN Price Earnings VS Forward Price EarningsRGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as RGEN.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of RGEN is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 73.72
EV/EBITDA 47.93
RGEN Per share dataRGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of RGEN may justify a higher PE ratio.
  • A more expensive valuation may be justified as RGEN's earnings are expected to grow with 22.86% in the coming years.
PEG (NY)4.26
PEG (5Y)117.88
EPS Next 2Y20.77%
EPS Next 3Y22.86%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RGEN Dividend Analysis

5.1 Amount

  • RGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RGEN Fundamentals: All Metrics, Ratios and Statistics

REPLIGEN CORP

NASDAQ:RGEN (3/6/2026, 8:00:02 PM)

After market: 119.99 0 (0%)

119.99

-5.04 (-4.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-24
Earnings (Next)04-27
Inst Owners110.6%
Inst Owner Change0.02%
Ins Owners0.45%
Ins Owner Change-2.86%
Market Cap6.76B
Revenue(TTM)738.26M
Net Income(TTM)48.89M
Analysts81.43
Price Target191.52 (59.61%)
Short Float %7.69%
Short Ratio5.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.52%
Min EPS beat(2)7.78%
Max EPS beat(2)9.25%
EPS beat(4)3
Avg EPS beat(4)5.23%
Min EPS beat(4)-6.83%
Max EPS beat(4)10.73%
EPS beat(8)5
Avg EPS beat(8)5.28%
EPS beat(12)8
Avg EPS beat(12)7.82%
EPS beat(16)12
Avg EPS beat(16)10.63%
Revenue beat(2)2
Avg Revenue beat(2)1.33%
Min Revenue beat(2)0.58%
Max Revenue beat(2)2.07%
Revenue beat(4)4
Avg Revenue beat(4)1.51%
Min Revenue beat(4)0.58%
Max Revenue beat(4)2.15%
Revenue beat(8)4
Avg Revenue beat(8)-0.01%
Revenue beat(12)4
Avg Revenue beat(12)-0.88%
Revenue beat(16)7
Avg Revenue beat(16)0.5%
PT rev (1m)-1.21%
PT rev (3m)0.18%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)0.05%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)-0.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.31%
Valuation
Industry RankSector Rank
PE 70.17
Fwd PE 60.26
P/S 9.16
P/FCF 73.72
P/OCF 57.56
P/B 3.21
P/tB 11.16
EV/EBITDA 47.93
EPS(TTM)1.71
EY1.43%
EPS(NY)1.99
Fwd EY1.66%
FCF(TTM)1.63
FCFY1.36%
OCF(TTM)2.08
OCFY1.74%
SpS13.11
BVpS37.39
TBVpS10.75
PEG (NY)4.26
PEG (5Y)117.88
Graham Number37.93
Profitability
Industry RankSector Rank
ROA 1.66%
ROE 2.32%
ROCE 2.11%
ROIC 1.65%
ROICexc 2.27%
ROICexgc 8.52%
OM 8.03%
PM (TTM) 6.62%
GM 52.65%
FCFM 12.42%
ROA(3y)0.67%
ROA(5y)2.96%
ROE(3y)0.95%
ROE(5y)3.98%
ROIC(3y)1.45%
ROIC(5y)3.72%
ROICexc(3y)2.01%
ROICexc(5y)5.28%
ROICexgc(3y)7.46%
ROICexgc(5y)30.51%
ROCE(3y)1.85%
ROCE(5y)4.75%
ROICexgc growth 3Y-45.78%
ROICexgc growth 5YN/A
ROICexc growth 3Y-39.51%
ROICexc growth 5Y-19.39%
OM growth 3Y-31%
OM growth 5Y-16.8%
PM growth 3Y-34.16%
PM growth 5Y-16.54%
GM growth 3Y-2.53%
GM growth 5Y-1.65%
F-Score6
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.91
Debt/EBITDA 3.93
Cap/Depr 32.68%
Cap/Sales 3.49%
Interest Coverage 250
Cash Conversion 85.06%
Profit Quality 187.52%
Current Ratio 8.37
Quick Ratio 7.12
Altman-Z 5.95
F-Score6
WACC10.77%
ROIC/WACC0.15
Cap/Depr(3y)44.28%
Cap/Depr(5y)98.33%
Cap/Sales(3y)4.79%
Cap/Sales(5y)7.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.54%
EPS 3Y-19.52%
EPS 5Y0.6%
EPS Q2Q%11.36%
EPS Next Y16.45%
EPS Next 2Y20.77%
EPS Next 3Y22.86%
EPS Next 5Y26.07%
Revenue 1Y (TTM)-6.05%
Revenue growth 3Y-2.7%
Revenue growth 5Y15.05%
Sales Q2Q%18.12%
Revenue Next Year12.66%
Revenue Next 2Y13.68%
Revenue Next 3Y14.28%
Revenue Next 5Y15.56%
EBIT growth 1Y282.37%
EBIT growth 3Y-32.87%
EBIT growth 5Y-4.28%
EBIT Next Year81.24%
EBIT Next 3Y41.89%
EBIT Next 5Y37.01%
FCF growth 1Y-36.98%
FCF growth 3Y3.04%
FCF growth 5Y20.36%
OCF growth 1Y-33.06%
OCF growth 3Y-11.97%
OCF growth 5Y13.4%

REPLIGEN CORP / RGEN FAQ

Can you provide the ChartMill fundamental rating for REPLIGEN CORP?

ChartMill assigns a fundamental rating of 5 / 10 to RGEN.


What is the valuation status for RGEN stock?

ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.


What is the profitability of RGEN stock?

REPLIGEN CORP (RGEN) has a profitability rating of 6 / 10.


What is the financial health of REPLIGEN CORP (RGEN) stock?

The financial health rating of REPLIGEN CORP (RGEN) is 7 / 10.


What is the earnings growth outlook for REPLIGEN CORP?

The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 16.45% in the next year.